Chimerix said today it will develop Cantex Pharmaceuticals’ Phase III-bound CX-01 as a first-line treatment for Acute Myeloid Leukemia (AML) and possibly other blood cancers, through an exclusive ...
Cullinan Therapeutics’ T-cell engager, CLN-049, has been proven tolerable and safe in an early-stage study in relapsed or refractory acute myeloid leukaemia (r/r AML) and myelodysplastic syndrome (MDS ...
Examining protein changes in peripheral blood cells just 24 hours after initiating chemotherapy for acute myeloid leukemia (AML) could predict 5-year overall survival, potentially allowing treatment ...
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31 ...
The classification of AML is based on the French-American-British system in which morphologic and immunophenotypic features of blast cells divide AML into 8 distinct subtypes labeled M0-M7. M3 is the ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML ...
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
SENTI-202, an allogeneic CAR NK cell therapy, offers a pre-manufactured option for aggressive cancers like AML, overcoming delays associated with autologous CAR T-cell therapies. The therapy's unique ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results